Alnylam initiates kardia-1 phase 2 study of zilebesiran (aln-agt) in patients with mild-to-moderate hypertension

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced initiation of kardia-1, a global phase 2 study evaluating the efficacy and safety of zilebesiran (pronounced “zile-bee-siran” and formerly known as aln-agt), an investigational subcutaneous rnai therapeutic targeting liver-expressed angiotensinogen (agt) in development for the treatment of hypertension. kardia-1 will evaluate zilebesiran as monotherapy across d
ALNY Ratings Summary
ALNY Quant Ranking